Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension symbols : Rytm save search
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
Published: 2023-10-17 (Crawled : 20:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -0.84%
H: 2.8%
C: 0.85%
obesityweek obesity year one setmelanotide pharmaceuticals extension study
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
Published: 2022-11-02 (Crawled : 12:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: -13.52%
obesityweek treatment obesity pharmaceuticals trials extension trial setmelanotide
Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -12.41%
H: 0.0%
C: -8.38%
obesity extension trial setmelanotide
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
Published: 2022-02-24 (Crawled : 18:00) - biospace.com/
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -10.16%
H: 1.13%
C: -3.46%
imcivree fda als setmelanotide set pdufa syndros
Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -1.33%
H: 1.34%
C: -1.04%
als positive setmelanotide set syndros
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.